ALGS
Aligos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.21
−0.16%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$38.78M
MomentumView details →
1D Return
−0.16%
YTD Return
−32.83%
RSI (14)
49.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$38.78M
RSI (14)
49.4
MomentumView details →
1D Return
−0.16%
YTD Return
−32.83%
SummaryUpdated Jun 1, 2026
Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company went public in October 2020 and focuses on developing novel therapeutics to address unmet medical needs in viral and liver diseases. Since its inception, Aligos has built a pipeline of drug candidates targeting chronic hepatitis B and non-alcoholic steatohepatitis (NASH), with several compounds currently in various phases of clinical trials.
Similar companies
Latest newsMore news →